Gelofusine affects the quality control performance of QuickVue point-of-care human chorionic gonadotropin test devices.
OBJECTIVE
To characterize the influence of Gelofusine (succinylated gelatin) on the performance of point-of-care testing (POCT) for human chorionic gonadotropin (hCG) devices.


METHODS
Three brands of urine and urine/serum hCG POCT devices were verified.


RESULTS
Succinylated gelatin affected the performance of the control band in the QuickVue hCG POCT devices. Alternative devices were not affected. The hCG test performance is not influenced.


CONCLUSIONS
Gelofusine affects specifically the quality control performance of the QuickVue hCG POCT devices.
de Boer
Douwe
D
Department of Clinical Chemistry, Maastricht University Medical Centre, The Netherlands. douwe.de.boer@mumc.nl
Houben
Christel
C
Bekers
Otto
O
Menheere
Paul P C A
PP
D006063:Chorionic Gonadotropin; D005260:Female; D006801:Humans; D019095:Point-of-Care Systems / Q000592:standards*; D011097:Polygeline; D011786:Quality Control; D011933:Reagent Kits, Diagnostic / Q000592:standards*
D006063:Chorionic Gonadotropin; D011933:Reagent Kits, Diagnostic; D011097:Polygeline